(Q34510307)

English

Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 August 2017

Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists (English)

1 reference

Europe PubMed Central

2 August 2017

0 references

type 2 diabetes

0 references

Daniel J. Cuthbertson

object named as

Daniel J Cuthbertson

1

0 references

object named as

Graham J Kemp

12

0 references

Munir Pirmohamed

object named as

Munir Pirmohamed

11

0 references

Christina Daousi

4

object named as

Christina Daousi

1 reference

Europe PubMed Central

2 August 2017

2

object named as

Andrew Irwin

1 reference

Europe PubMed Central

2 August 2017

author name string

Chris J Gardner

3

1 reference

Europe PubMed Central

2 August 2017

Tej Purewal

5

1 reference

Europe PubMed Central

2 August 2017

Niall Furlong

6

1 reference

Europe PubMed Central

2 August 2017

Niru Goenka

7

1 reference

Europe PubMed Central

2 August 2017

E Louise Thomas

8

1 reference

Europe PubMed Central

2 August 2017

Valerie L Adams

9

1 reference

Europe PubMed Central

2 August 2017

Sudeep P Pushpakom

10

1 reference

Europe PubMed Central

2 August 2017

language of work or name

0 references

publication date

6 December 2012

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

7

1 reference

Europe PubMed Central

2 August 2017

12

1 reference

Europe PubMed Central

2 August 2017

e50117

1 reference

Europe PubMed Central

2 August 2017

copyright license

Creative Commons Attribution 4.0 International

6 December 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Quantifying the improvement of surrogate indices of hepatic insulin resistance using complex measurement techniques

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516516

7 July 2018

Human fatty liver disease: old questions and new insights

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516516

7 July 2018

Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516516

7 July 2018

Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516516

7 July 2018

Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516516

7 July 2018

Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516516

7 July 2018

Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516516

7 July 2018

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516516

7 July 2018

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516516

7 July 2018

Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516516

7 July 2018

Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516516

7 July 2018

Benefits of lifestyle modification in NAFLD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516516

7 July 2018

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled tr

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516516

7 July 2018

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516516

7 July 2018

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516516

7 July 2018

Incretin mimetics as a novel therapeutic option for hepatic steatosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516516

7 July 2018

Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516516

7 July 2018

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516516

7 July 2018

Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516516

7 July 2018

Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516516

7 July 2018

Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516516

7 July 2018

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050117

21 January 2018

Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050117

21 January 2018

Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050117

21 January 2018

Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050117

21 January 2018

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050117

21 January 2018

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050117

21 January 2018

Hypothyroidism in a patient with non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050117

21 January 2018

Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050117

21 January 2018

Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516516

27 October 2018

Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516516

27 October 2018

Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3516516

27 October 2018

Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series

1 reference

https://pubmed.ncbi.nlm.nih.gov/23236362

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23236362

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/23236362

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23236362

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23236362

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0050117

1 reference

Europe PubMed Central

2 August 2017

2012PLoSO...750117C

0 references

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34510307&oldid=1866038484"